Compare Wayfair Inc (W) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wayfair Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Wayfair Inc trades at $105.76 (market cap $14.40B), while State Street SPDR S&P Biotech ETF trades at $152.22 (market cap $10.11B). The key difference: Wayfair Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 2,102,856). Which is the better fit depends on your goals — on Pluang, investors hold Wayfair Inc for 8 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| W | XBI | |
|---|---|---|
Market Cap | $14.40B | $10.11B |
Volume | 2,102,856 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $119.05 | $169.55 |
52-Week Low | $57.40 | $104.99 |
Typical Hold Time | 8 Days | 37 Days |
Enterprise Value | $16.73B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $105.70, up 1.18% today, with a bullish technical signal and strong analyst support. The stock shows positive earnings surprises in recent quarters, though it remains unprofitable with a net income margin of -2.49%. Revenue growth is modest, and the company maintains a solid gross profit margin of 30.05%. Recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook is cautiously optimistic with a consensus price target of $114.13, implying upside potential. Key risks include persistent losses, high debt-to-asset ratio, and competitive pressures. Investor sentiment is positive, but profitability challenges and macroeconomic headwinds warrant careful monitoring for sustained growth.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
